Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001140361-25-013973
Filing Date
2025-04-15
Accepted
2025-04-15 16:39:35
Documents
18
Period of Report
2025-05-23

Document Format Files

Seq Description Document Type Size
1 PRE 14A ny20042463x1_pre14a.htm   iXBRL PRE 14A 1769147
3 logo_nektar.jpg GRAPHIC 14135
4 ny20042463x1_barchart01.jpg GRAPHIC 173557
5 ny20042463x1_pvpchart01x1.jpg GRAPHIC 212153
6 ny20042463x1_pvpchart02.jpg GRAPHIC 176356
  Complete submission text file 0001140361-25-013973.txt   4349598

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION - SCHEMA nktr-20250523.xsd EX-101.SCH 2117
20 EXTRACTED XBRL INSTANCE DOCUMENT ny20042463x1_pre14a_htm.xml XML 330097
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 000-24006 | Film No.: 25840085
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)